[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362590-105":59,"doc-detail-362590-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","risk-of-breast-and-ovarian-cancer-after-prophylactic-mastectomy-and-salpingo-oophorectomy-in-brca12-germline-variant-carriers-a-retrospective-cohort-study-from-a-single-german-center","Risk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo-Oophorectomy in BRCA1/2 Germline Variant Carriers - A Retrospective Cohort Study From a Single German Center","","Evaluate cancer prevalence in BRCA1/2 germline variant carriers after prophylactic surgery in a single German center cohort. Retrospective inclusion covered 875 women tested positive for gPV between 2002 and 2022, with mean 7.2 years follow-up (0–44). Analyses compared breast/ovarian cancer–diseased (n=643) versus non-diseased (n=232) carriers. Results reported no breast cancer after prophylactic bilateral mastectomy and a lower ipsilateral secondary cancer rate after mastectomy (4.3%) than after breast-conserving surgery (18.3%).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/risk-of-breast-and-ovarian-cancer-after-prophylactic-mastectomy-and-salpingo-oophorectomy-in-brca12-germline-variant-carriers-a-retrospective-cohort-study-from-a-single-german-center/362590/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/risk-of-breast-and-ovarian-cancer-after-prophylactic-mastectomy-and-salpingo-oophorectomy-in-brca12-germline-variant-carriers-a-retrospective-cohort-study-from-a-single-german-center/362590.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main purpose?","Question",{"text":112,"@type":113},"To evaluate breast and ovarian cancer prevalence after prophylactic mastectomy and prophylactic bilateral salpingo-oophorectomy in BRCA1/2 germline variant carriers in a single-center cohort.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were included in the retrospective cohort?",{"text":117,"@type":113},"875 women tested positive for a BRCA1/BRCA2 germline variant between 2002 and 2022 at the Technical University Munich center for hereditary breast and ovarian cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about cancer occurrence after prophylactic surgery?",{"text":121,"@type":113},"The analysis found no breast cancer after prophylactic bilateral mastectomy, and it reported low ovarian cancer findings incidentally after PBSO. It also showed lower ipsilateral secondary cancer after mastectomy than after breast-conserving surgery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362590,1790192960,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nRisk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo-Oophorectomyin BRCA1/2 Germline Variant Carriers: A Retrospective Cohort Study From a Single German Center  \nSara Mendes1  | Maryam Yahiaoui-Doktor2 | Eva Maria Fallenberg3 | Marion Kiechle1  | Sabine Grill1  \n1Department of Gynecology and Obstetrics, University Hospital Klinikum Rechts der Isar, Technical University Munich (TUM), Munich,  \nGermany | 2Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany | 3Department of Diagnostic and Interventional Radiology, University Hospital Klinikum Rechts der Isar, Technical University of Munich (TUM), Munich, Germany  \nCorrespondence: Sara Mendes (sara.mendes@mri.tum.de)  \nReceived: 5 August 2025 | Revised: 17 December 2025 | Accepted: 20 February 2026  \nKeywords: cancer prevalence | gPV BRCA1/2 germline variants | hereditary breast and ovarian cancer | prophylactic mastectomy | prophylactic salpingooophorectomy  \nABSTRACT  \nBackground: As the data on BRCA1/2-associated breast and ovarian cancer prevalence after prophylactic surgery has not been exhaustively investigated yet, we aimed to evaluate the cancer prevalence in a single center cohort of BRCA1 and BRCA2 carriers after conducting prophylactic mastectomy, as well as prophylactic bilateral salpingo-oophorectomy (PBSO) respectively. Methods: We included 875 women that were tested positive for a germline variant in the BRCA1/BRCA2 gene (gPV) between 2002 and 2022 at the Center of Hereditary Breast and Ovarian Cancer of the Technical University Munich Germany. Mean followup was 7.2 years (range 0–44 years; 95% CI: 6.70 to 7.70). We differentiated breast and/or ovarian cancer diseased (n = 643) and non-diseased BRCA1/2 carriers (n = 232) .  \nResults: Our analysis confirmed the effectiveness of prophylactic surgeries in genetically predisposed women with a gPV in the BRCA1/2 gene. We observed no breast cancer after prophylactic bilateral mastectomy, 2 contralateral breast cancer diseases after contralateral prophylactic mastectomy and 1 extraovarian serous adenocarcinoma after PBSO. Within the entire study collective, a total of 293 have undergone PBSO, with 6 women having an incidental finding of ovarian cancer and STIC respectively (=2.0%; 1.7% gBRCA1 and 0.3% gBRCA2). Our data suggests that, particularly regarding ipsilateral secondary cancer (ISC), higher oncological safety can be achieved through mastectomy rather than breast-conserving surgery (BCS) . In the group of patients who had a second breast cancer and were treated with BCS during their first cancer, 18.3% showed an ISC. Within the patients who were first treated with a mastectomy, only 4.3% showed an ISC.  \nConclusions: Prophylactic surgeries demonstrate high oncological effectiveness in gPV BRCA1/2 carriers. In particular, mastectomy may provide greater protection against ISC compared with BCS. Further studies will have to be conducted to compare ipsilateral cancer prevalence after breast-sparing surgery and mastectomy.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71691 1 of 7  \n[https://doi.org/10.1002/cam4.71691](https://doi.org/10.1002/cam4.71691)  \n1 | Introduction  \nBreast cancer is the most common cancer among women with an evaluated lifetime risk of 13.2%[1] . Familial susceptibility to breast cancer thereby accounts for approximately 30%–40% of all breast cancer cases. An estimated 10% of all breast cancers are developed monogenic, meaning that a single disease-causing (pathogenic) variant is responsible for the increased risk. The majority of the monogenic inherited breast cancer diseases is attributed to the tumor suppressor","cbCaiqWu1RDx25Zk","https://ap.wps.com/l/cbCaiqWu1RDx25Zk","pdf",386553,"English","# Introduction\n## Breast cancer risk and BRCA1/BRCA2 genetics\n## Screening limitations for ovarian cancer\n## Rationale for prophylactic surgery","[{\"question\":\"What is the study’s main purpose?\",\"answer\":\"To evaluate breast and ovarian cancer prevalence after prophylactic mastectomy and prophylactic bilateral salpingo-oophorectomy in BRCA1/2 germline variant carriers in a single-center cohort.\"},{\"question\":\"Who were included in the retrospective cohort?\",\"answer\":\"875 women tested positive for a BRCA1/BRCA2 germline variant between 2002 and 2022 at the Technical University Munich center for hereditary breast and ovarian cancer.\"},{\"question\":\"What did the results show about cancer occurrence after prophylactic surgery?\",\"answer\":\"The analysis found no breast cancer after prophylactic bilateral mastectomy, and it reported low ovarian cancer findings incidentally after PBSO. It also showed lower ipsilateral secondary cancer after mastectomy than after breast-conserving surgery.\"}]","Risk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo-Oophorectomy in BRCA1/2 Germline Variant Carriers - A Retrospective Cohort Study From a Single German Center | PDF",1790148469,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97f87e9f75dd668665598ed86d16f9cf.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44c3fdf0431fe79816e78efea64c7809.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b094e348b6b20b507fe1f454b9f17102.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/619e7b2f0750bdbf24597e376b78a863.webp",980,1287]